Business
Mymetics receives HIV Vaccine Funding from the NIH
Mymetics receives HIV Vaccine Funding from the NIH.
About this update from Mymetics Corp.
[{"type":"text","content":"\n\n\n\nMymetics receives HIV Vaccine Funding from the NIH\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMymetics receives HIV Vaccine Funding from the NIH\n- Funding to prepare Mymetics' cold chain independent needle free mucosal virosome HIV vaccine candidate for clinical trials\n- Collaboration with Texas Biomedical Research Institute and University of Louisiana at Lafayette\n- Total award USD 8.5 million over 5 years, with USD 1.9 million budget in the first year\nPR Newswire\nEPALINGES, Switzerland, April 29, 2019\n\n\n\nEPALINGES, Switzerland, April 29, 2019 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the National Institutes of Health (NIH) has awarded Mymetics and Texas Biomedical Research Institute (Texas Biomed) a five-year grant for the project called \"Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels\". \nThe project has the objective to prepare Mymetics' promising HIV-1 vaccine candidate for clinical trials. The vaccine candidate is based upon Mymetics' virosomes, enveloped virus-like particles that display on their surface rationally designed HIV-1 antigens. The vaccine is created to induce protective mucosal antibodies acting as a frontline defense against sexual HIV transmission. An earlier formulation of the vaccine candidate has shown safety and immunogenicity in a Phase I clinical trial in healthy women. Two independent non-human primate studies demonstrated the safety and high efficacy of the virosome-based vaccine in Chinese and Indian-origin rhesus macaques against repeated low-dose intravaginal challenges with a monkey AIDS virus, a so-called tier 2 R5 SHIV that shares key biological features with transmitted forms of HIV-1. Mymetics recently finished a European Horizon 2020 funded project, where Mymetics developed adjuvanted new solid powder forms of the vaccine, which can be directly administered to mucosal tiss...